english
nederlands
Indymedia NL
Vrij Media Centrum Nederland
Indymedia NL is een onafhankelijk lokaal en mondiaal vrij communicatie orgaan. Indymedia biedt een andere kijk op het nieuws door een open publicatie methode van tekst, beeld & geluid.
> contact > zoek > archief > hulp > doe mee > publiceer nieuws > open nieuwslijn > disclaimer > chat
Zoek

 
Alle Woorden
Elk Woord
Bevat Media:
Alleen beelden
Alleen video
Alleen audio

Dossiers
Agenda
CHAT!
LINKS

European NewsReal

MDI klaagt Indymedia.nl aan
Rechtszaak Deutsche Bahn tegen Indymedia.nl
Onderwerpen
anti-fascisme / racisme
europa
feminisme
gentechnologie
globalisering
kunst, cultuur en muziek
media
militarisme
natuur, dier en mens
oranje
vrijheid, repressie & mensenrechten
wereldcrisis
wonen/kraken
zonder rubriek
Events
G8
Oaxaca
Schinveld
Schoonmakers-Campagne
Hulp
Hulp en tips voor beginners
Een korte inleiding over Indymedia NL
De spelregels van Indymedia NL
Hoe mee te doen?
Doneer
Steun Indymedia NL financieel!
Rechtszaken kosten veel geld, we kunnen elke (euro)cent gebruiken!

Je kunt ook geld overmaken naar bankrekening 94.32.153 tnv Stichting Vrienden van Indymedia (IBAN: NL41 PSTB 0009 4321 53).
Indymedia Netwerk

www.indymedia.org

Projects
print
radio
satellite tv
video

Africa
ambazonia
canarias
estrecho / madiaq
kenya
nigeria
south africa

Canada
hamilton
london, ontario
maritimes
montreal
ontario
ottawa
quebec
thunder bay
vancouver
victoria
windsor
winnipeg

East Asia
burma
jakarta
japan
manila
qc

Europe
alacant
andorra
antwerpen
armenia
athens
austria
barcelona
belarus
belgium
belgrade
bristol
bulgaria
croatia
cyprus
estrecho / madiaq
euskal herria
galiza
germany
grenoble
hungary
ireland
istanbul
italy
la plana
liege
lille
madrid
malta
marseille
nantes
netherlands
nice
norway
oost-vlaanderen
paris/île-de-france
poland
portugal
romania
russia
scotland
sverige
switzerland
thessaloniki
toulouse
ukraine
united kingdom
valencia
west vlaanderen

Latin America
argentina
bolivia
brasil
chiapas
chile
chile sur
colombia
ecuador
mexico
peru
puerto rico
qollasuyu
rosario
santiago
tijuana
uruguay
valparaiso

Oceania
adelaide
aotearoa
brisbane
burma
darwin
jakarta
manila
melbourne
oceania
perth
qc
sydney

South Asia
india
mumbai

United States
arizona
arkansas
atlanta
austin
baltimore
big muddy
binghamton
boston
buffalo
charlottesville
chicago
cleveland
colorado
columbus
danbury, ct
dc
hampton roads, va
hawaii
houston
hudson mohawk
idaho
ithaca
kansas city
la
madison
maine
miami
michigan
milwaukee
minneapolis/st. paul
new hampshire
new jersey
new mexico
new orleans
north carolina
north texas
nyc
oklahoma
omaha
philadelphia
pittsburgh
portland
richmond
rochester
rogue valley
saint louis
san diego
san francisco
san francisco bay area
santa barbara
santa cruz, ca
seattle
tallahassee-red hills
tampa bay
tennessee
united states
urbana-champaign
utah
vermont
western mass
worcester

West Asia
armenia
beirut
israel
palestine

Topics
biotech

Process
discussion
fbi/legal updates
indymedia faq
mailing lists
process & imc docs
tech
volunteer
Credits
Deze site is geproduceerd door vrijwilligers met free software waar mogelijk.

De software die we gebruiken is beschikbaar op: mir.indymedia.de
een alternatief is te vinden op: active.org.au/doc

Dank aan indymedia.de en mir-coders voor het creëren en delen van mir!

Contact:
info @ indymedia.nl
Novartis in India: Exploiting AIDS-victims
A.L.F. Crime Investigation Agency (CIA) - 18.04.2008 12:58

This information campaign is dedicated to the victims of Novartis AG: Gunned-down Brazilian farmers - Tortured, maimed and killed animals in labs - Victims of sexual exploitation by the management - Africans left to die for profit - Patients poisoned and killed with harmful drugs - Babies fed with unhealthy food

Part 6: Payback: Novartis To Slash Investment In India

The Novartis CEO Vasella says he will switch hundreds of millions of dollars in planned investments from India to other locations, primarily, China, in response to an Indian court ruling that he says weakens intellectual property rights on new meds.

In an interview with The Financial Times following the rejection this month of his bid to protect the patent on the Gleevec cancer med (in other countries sold as Glivec), Vasella says “concrete plans” for investments in research in India stalled during the trial and Novartis will now go elsewhere. Novartis is already expanding in China, despite concerns over corruption and quality control.

Novartis had appealed against an earlier Indian ruling to reject patents on Gleevec. The court argued that “incremental innovation” didn’t qualify it as a new chemical entity justifying protection. The drugmaker says the interpretation violated World Trade Organization agreements and would be a disincentive for investment because much innovation occurs through incremental research.

The case became a rallying point for non-governmental organizations, which mounted a campaign against Novartis to drop the legal action. Campaigners argued that tougher patent rules were undermining India’s pivotal role in providing cheap medicines for the developing world through its low-cost generic drugs industry.

Some HIV/AIDS advocacy groups are calling on Novartis to drop its legal challenge, saying that if the company wins the case it could restrict access to antiretroviral drugs for millions of people worldwide.

Although some Indian drug companies and groups say that Gleevec is a new formulation of a drug developed before 1995, Novartis says that it is an improved drug. Decisions concerning patents on some newer HIV/AIDS drugs in India have not been announced. If Novartis wins the case, it could potentially set a precedent for other pharmaceutical companies seeking patent protection for drugs, including antiretrovirals, some HIV/AIDS advocates have said.

According to Medecins Sans Frontieres, most of the roughly 9,000 pending patent applications would be affected by this ongoing case. MSF, which relies on India for about 80% of the AIDS drugs it uses to provide 80,000 people worldwide with access to treatment, in a statement said that if India is "made to change its law, many of these medicines could become patented, making them off-limits to the generic competition that has proved to bring prices down".

 http://www.pharmalot.com/2007/08/payback-novartis-to-slash-investment-in-india/
 http://www.kaisernetwork.org/daily_reports/rep_index.cfm?DR_ID=43357


- E-Mail: alfcia_vries@mail2world.com Website: http://www.novartiskills.eu
 

Lees meer over: natuur, dier en mens

aanvullingen
> indymedia.nl > zoek > archief > hulp > doe mee > publiceer nieuws > open nieuwslijn > disclaimer > chat
DISCLAIMER: Indymedia NL werkt volgens een 'open posting' principe om zodoende de vrijheid van meningsuiting te bevorderen. De berichten (tekst, beelden, audio en video) die gepost zijn in de open nieuwslijn van Indymedia NL behoren toe aan de betreffende auteur. De meningen die naar voren komen in deze berichten worden niet zonder meer door de redactie van Indymedia NL gesteund. Ook is het niet altijd mogelijk voor Indymedia NL om de waarheid van de berichten te garanderen.